Amphotericin B fat emulsion
PreclinicalSmall molecule
Amphotericin B fat emulsion is one of 4 small molecule programs targeting Visceral Leishmaniasis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Visceral Leishmaniasis
#DrugCompanyPhaseTrials
1LXE408
NovartisPhase 2
Cysteine Hydrochloride
NovartisPreclinical
Feosol
AAuerbach Hematology Oncology Associates P C
Preclinical
Amphotericin B fat emulsion
BBanaras Hindu University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Visceral Leishmaniasis1 trial
Amphotericin B Treatment in Visceral Leishmaniasis
Completed·—·N/A·NCT00310505·1,500 enrolled
Safety and Efficacy1 trial
A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar
Completed·—·Phase 2·NCT00497601·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amphotericin B fat emulsion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBanaras Hindu University